Albany, NY -- (SBWIRE) -- 07/18/2019 -- Vulvovaginal Candidiasis Market Insights, Epidemiology and Market Forecast-2028

1. Almost 80-90% of Vulvovaginal candidiasis is caused by Candida albicans.
2. An estimated 75% of women will have at least one episode of Vulvovaginal candidiasis, and 40–45% will have two or more episodes.
3. At some point in their lifetime, nearly 75% of all women experience an attack of vulvovaginal candidiasis, with approximately 50% of college-aged women having an episode.

(Albany, US) DelveInsight launched a new report on Vulvovaginal Candidiasis Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Vulvovaginal Candidiasis market report covers a descriptive overview and comprehensive insight of the Vulvovaginal Candidiasis epidemiology and Vulvovaginal Candidiasis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Vulvovaginal Candidiasis market report provides insights on the current and emerging therapies.
3. Vulvovaginal Candidiasis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Vulvovaginal Candidiasis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Vulvovaginal Candidiasis market.

Request for sample pages

"Recurrent Vulvovaginal Candidiasis (RVVC), usually defined as four or more episodes of symptomatic Vulvovaginal Candidiasis within 1 year, affects a small percentage of women (<5%)."

In the current Vulvovaginal Candidiasis market scenario, recommended therapies to possibly slow the progression of the disease include topical or oral antifungals. The current availability of over-the-counter (OTC) Vulvovaginal Candidiasis medications is a convenient option for many women. Preparations for intravaginal administration of antifungal intravaginal agents are available as an OTC. However, self-medication with OTC preparations should be advised only for women who have been gone through vulvovaginal candidiasis diagnosis and who have a recurrence of the same symptoms. Currently available options for Vulvovaginal Candidiasis treatment include antifungal intravaginal agents such as butoconazole, clotrimazole, miconazole, Fluconazole, and tioconazole are available as OTC.

Acute and recurrent Vulvovaginal Candidiasis are serious conditions with significant morbidity and with very limited oral treatment options. No product is approved for recurrent Vulvovaginal Candidiasis prevention, and current Vulvovaginal Candidiasis treatment alternatives have significant limitations, particularly in patients with other comorbidities and those who are taking certain concomitant medications, are pregnant or are experiencing episodes caused by an azole-resistant micro-organism. Among patients with infrequent Vulvovaginal Candidiasis episodes, unmet needs are significant due to a combination of resistance, recurrence, cure rates, and lack of new mechanisms. In addition to this, Fluconazole, which is approved for Vulvovaginal Candidiasis, gives only therapeutic cure rate of 55% and management during pregnancy and Vulvovaginal Candidiasis treatment of moderate-to-severe Vulvovaginal Candidiasis, recurrent Vulvovaginal Candidiasis and Vulvovaginal Candidiasis caused by fluconazole-resistant Candida are not fully addressed by oral fluconazole. There are no oral alternatives for Vulvovaginal Candidiasis patients, who do not respond to or tolerate fluconazole, and there are no FDA-approved products for recurrent Vulvovaginal Candidiasis treatment.

Vulvovaginal Candidiasis market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and also expected the launch of Vulvovaginal Candidiasis emerging therapies during the forecast period of 2019-2028.

Major players involved are:
1. Scynexis
2. ProFem GmbH
3. Mycovia Pharmaceuticals
And many others

Drugs involved are-
1. Candiplus
2. Ibrexafungerp
3. VT-1161
And many others

Table of contents

1. Report Introduction
2. Vulvovaginal Candidiasis Market Overview at a Glance
3. Vulvovaginal Candidiasis Disease Background and Overview
4. Vulvovaginal Candidiasis Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. Vulvovaginal Candidiasis Geography-wise Prevalent Cases
4.3. United States
4.4. EU-5
4.4.1.Assumptions and Rationale
4.4.2.Germany
4.4.3.Italy
4.4.4.Spain
4.4.5.France
4.4.6.United Kingdom
4.5. Japan
5. Vulvovaginal Candidiasis Treatments & Medical Practices
6. Vulvovaginal Candidiasis Marketed Products
6.1. Diflucan: Pfizer
7. Vulvovaginal Candidiasis Key Emerging Therapies
7.1. Key Cross Competition
7.2. Candiplus: ProFem GmbH
7.3. Ibrexafungerp: Scynexis
7.4. VT-1161: Mycovia Pharmaceuticals
8. Vulvovaginal Candidiasis Market Size
8.1. Key Findings
8.2. Total 7MM Vulvovaginal Candidiasis Market Analysis
8.3. 7MM: Country-Wise Market Analysis
8.3.1.United States Market Size
8.3.2.Germany Market Size
8.3.3.France Market Size
8.3.4.United Kingdom Market Size
8.3.5.Spain Market Size
8.3.6.Italy Market Size
8.3.7.Japan Market Size
8.4. Market Drivers
9. Market Barriers
10. Vulvovaginal Candidiasis Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight